City of Health and Science of Turin

Turin 10126

1 studies enrolling now · 4 studies all time

What they study most

Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor, MF, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis, Short Bowel Syndrome

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Running, not enrolling
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders — Stopped early